Delving into the Latest Updates on L-Phencynonate Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(L)-phencynonate, (L)-phencynonate hydrochloride, L-LPC

+ [12]

Target

mAChRs

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Other DiseasesNervous System DiseasesCardiovascular Diseases+ [1]

Active Indication

Motion SicknessIschemic strokeBrain Infarction+ [1]

Inactive Indication

Cerebral Infarction

Originator Organization

Beijing Sihuan Pharmaceutical Co. Ltd.

Active Organization

Institute of Poisons and Drugs, Academy of Military Medical Sciences, PLA

Beijing Sihuan Pharmaceutical Co. Ltd.

Beijing Wellso Pharmaceutical Co., Ltd.

Inactive Organization

Academy of Military Medical Sciences

Drug Highest PhaseApproved

First Approval Date-

RegulationSpecial Review Project (CN)

Login to view timeline

Structure

Molecular FormulaC22H31NO3

InChIKeyROZOEEGFKDFEFP-JLPZCGHASA-N

CAS Registry230313-75-4

View All Structures (2)

A Multicenter, Double-Blind, Placebo Controlled, Phase Ⅱa clinical trial to enroll 120 patients with Vertigo Caused By Posterior Circulation Infarction during 7 days, then to evaluate the efficacy of different dose of Levophencynonate Hydrochloric, and provide the effective dosage for phase IIb clinical study, to study the safety of Levophencynonate Hydrochloric.

Start Date01 Jan 2014

Sponsor / Collaborator

Sihuan Pharmaceutical Holdings Group Ltd.

100 Clinical Results associated with L-Phencynonate Hydrochloride

Login to view more data

100 Translational Medicine associated with L-Phencynonate Hydrochloride

Login to view more data

100 Patents (Medical) associated with L-Phencynonate Hydrochloride

Login to view more data

24

Literatures (Medical) associated with L-Phencynonate Hydrochloride

01 May 2024·Chirality

The stereoselective pharmacokinetics of the desmethyl‐phencynonate hydrochloride in beagle dogs

Article

Author: Wang, Xiaoying ; Zhang, Zhenqing ; Xiong, Shan ; Yin, Lan ; Sun, Junying ; Li, Yuexin ; Li, Jinglai

AbstractThe aim of this study was to investigate the chiral inversion and the stereoselective pharmacokinetic profiles of desmethyl‐phencynonate hydrochloride after administration of the single isomer and its racemate to beagle dogs. A liquid chromatography with tandem mass spectrometry (LC–MS/MS) method was established for determination of the stereoisomers on chiral columns in beagle dog plasma, which met all the requirements. The chiral inversion in dogs of the desmethyl‐phencynonate hydrochloride were studied after administration of the single isomer or the racemic modification. The stereoselective pharmacokinetic profiles of the desmethyl‐phencynonate hydrochloride were studied by assays for simultaneous isomers after administration of the racemic modification. The results showed that the absorption of the Rconfiguration dosed as the single isomer was higher than it dosed as the racemic modification. The AUC(0‐t), AUC(0‐∞), and Cmax of the Sconfiguration were much higher than those of Rconfiguration after oral administration of the racemic desmethyl‐phencynonate hydrochloride. The chiral inversion of desmethyl‐phencynonate isomers could not occur in dogs after administration of the Rconfiguration.

01 Dec 2022·Annals of Surgical Oncology

Robotic Versus Laparoscopic Left and Extended Left Hepatectomy: An International Multicenter Study Propensity Score-Matched Analysis

Article

Author: Sucandy, Iswanto ; Cheung, Tan-To ; Prieto, Mikel ; Chong, Charing C ; Lee, Jae-Hoon ; Lai, Eric C ; Choi, Sung Hoon ; Sutcliffe, Robert P ; Goh, Brian K P ; Chong, Yvette ; Wang, Xiaoying ; Efanov, Mikhail ; Park, James O ; Rayman, Shlomi ; Choi, Gi-Hong ; Scatton, Olivier ; Pratschke, Johann ; Kingham, T Peter ; Rotellar, Fernando ; Troisi, Roberto I ; Chiow, Adrian K H ; Tang, Chung-Ngai ; Liu, Rong ; Fuks, David ; Marino, Marco V ; D'Hondt, Mathieu ; Han, Ho-Seong

BACKGROUNDControversies exist among liver surgeons regarding clinical outcomes of the laparoscopic versus the robotic approach for major complex hepatectomies. The authors therefore designed a study to examine and compare the perioperative outcomes of laparoscopic left hepatectomy or extended left hepatectomy (L-LH/L-ELH) versus robotic left hepatectomy or extended left hepatectomy (R-LH/R-ELH) using a large international multicenter collaborative database.METHODSAn international multicenter retrospective analysis of 580 patients undergoing L-LH/L-ELH or R-LH/R-ELH at 25 specialized hepatobiliary centers worldwide was undertaken. Propensity score-matching (PSM) was used at a 1:1 nearest-neighbor ratio according to 15 perioperative variables, including demographics, tumor characteristics, Child-Pugh score, presence of portal hypertension, multiple resections, histologic diagnosis, and Iwate difficulty grade.RESULTSBefore the PSM, 190 (32 %) patients underwent R-LH/R-ELH, and 390 (68 %) patients underwent L-LH/L-ELH. After the matching, 164 patients were identified in each arm without significant differences in demographics, preoperative variables, medical history, tumor pathology, tumor characteristics, or Iwate score. Regarding intra- and postoperative outcomes, the rebotic approach had significantly less estimated blood loss (EBL) (100 ml [IQR 200 ml] vs 200 ml [IQR 235 ml]; p = 0.029), fewer conversions to open operations (n = 4 [2.4 %] vs n = 13, [7.9 %]; p = 0.043), and a shorter hospital stay (6 days [IQR 3 days] vs 7 days [IQR 3.3 days]; p = 0.009).CONCLUSIONBoth techniques are safe and feasible in major hepatic resections. Compared with L-LH/L-ELH, R-LH/R-ELH is associated with less EBL, fewer conversions to open operations, and a shorter hospital stay.

10 Feb 2022·Evidence-Based Complementary and Alternative MedicineQ4 · MEDICINE

Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common-Type COVID-19: A Randomized, Controlled, Multicenter Clinical Study

Q4 · MEDICINE

ArticleOA

Author: Yan, Xixin ; Mei, Jianqiang ; Liu, Qingquan ; Yuan, Yadong ; Wu, Lei ; Jiang, Rongmeng ; Gao, Yong ; Shang, Huanxia ; Xu, Xiaolong ; Hu, Jing ; Zhang, Ling ; Lian, Bo ; Wu, Shucai ; Zhang, Xin

Background. Lianhua Qingke (LH) tablets is an effective traditional Chinese medicine against various viral infections, especially in relieving coughing. However, its effects on COVID-19 are unknown. Methods. To examine the therapeutic effectiveness of LH tablets in COVID-19 patients with mild and common types, a randomized, multicenter, controlled study was carried out. COVID-19 cases were randomized to undergo routine treatment with or without LH tablets (4 tablets, three times a day) for 14 days. The primary endpoints were the rate of achieving clinical symptom resolution and the corresponding time. Results. There were 144 participants in the full analysis set (72 each in the LH and control groups). The LH group participants had elevated symptom alleviation rate at 14 days compared with control cases (FAS: 98.61% vs. 84.72%,

p

= 0.0026). In comparison with control group participants, the LH group participants had reduced median time to clinical symptom alleviation (median: 4 vs. 7 days,

p

< 0.0001). Higher resolution rates of coughing (98.44% vs. 84.51%,

p

= 0.0045) and expectoration (100% vs. 82.35%,

p

= 0.0268) were observed in the LH group. Times to recovery of fever (median: 2 vs. 3 days,

p

= 0.0007), coughing (median: 4 vs. 7 days,

p

< 0.0001), and expectoration (median: 3 vs. 6 days,

p

< 0.0001) were also notably shorter in the LH group. Moreover, the LH group had elevated improvement rates in chest computed tomography signs (FAS: 86.11% vs. 72.22%,

p

= 0.0402) and clinical cure at day 28 (FAS: 83.33% vs. 68.06%,

p

= 0.0326). However, no differences were found in the laboratory test and viral assay. Serious adverse events were not detected. Conclusion. These preliminary findings indicate LH tablets may be effective in symptomatic COVID-19, especially in relieving coughing. This trial was registered in Chinese Clinical Trial Registry (ChiCTR2100042069).

100 Deals associated with L-Phencynonate Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	N05CM	DB16011

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Motion Sickness	CN	Beijing Wellso Pharmaceutical Co., Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cerebral Infarction	Phase 3	CN	Academy of Military Medical Sciences	07 May 2014
Cerebral Infarction	Phase 3	CN	Beijing Sihuan Pharmaceutical Co. Ltd.	07 May 2014
Vertigo	Phase 3	CN	Academy of Military Medical Sciences	07 May 2014
Motion Sickness	Phase 3	CN	Institute of Poisons and Drugs, Academy of Military Medical Sciences, PLA	29 Mar 2014
Ischemic stroke	Phase 2	CN	Beijing Sihuan Pharmaceutical Co. Ltd.	05 May 2016
Ischemic stroke	Phase 2	CN	Institute of Poisons and Drugs, Academy of Military Medical Sciences, PLA	05 May 2016
Brain Infarction	Phase 2	CN	Institute of Poisons and Drugs, Academy of Military Medical Sciences, PLA	07 May 2014
Vertigo	Phase 2	CN	Beijing Sihuan Pharmaceutical Co. Ltd.	07 May 2014
Vertigo	Phase 2	CN	Institute of Poisons and Drugs, Academy of Military Medical Sciences, PLA	07 May 2014